Document is current
Any future updates will be listed below
-
Authors
Shimoda, Kazuya https://orcid.org/0000-0002-2555-8188
Takenaka, Katsuto
Kitamura, Haruna
Dohi, Koji
Yoshimoto, Riki
Kirito, Keita
-
Funding
Funding for this research was provided by:
PharmaEssentia Japan KK
- License Information
-
More Information
Article History
Received: 5 August 2025
Revised: 8 December 2025
Accepted: 15 December 2025
First Online: 4 March 2026
Declarations
:
: Kazuya Shimoda has received speaker fees from Novartis Pharma, PharmaEssentia Japan, and GlaxoSmithKline; consulting fees from Sumitomo Pharma, GlaxoSmithKline, and Merck; research funding from AstraZeneca, Meiji Seika Pharma, Incyte Biosciences Japan, and PharmaEssentia Japan; and educational/academic donations from Chugai Pharmaceutical, Kyowa Kirin, AbbVie, Shionogi, Daiichi Sankyo, Otsuka Pharmaceutical, Eisai, Nippon Kayaku, and Asahi Kasei Medical. Katsuto Takenaka has received speaker fees from PharmaEssentia Japan and Novartis Pharma; writing fees from PharmaEssentia Japan; and research funding from PharmaEssentia Japan. Keita Kirito has received speaker fees from Novartis Pharma, Takeda Pharmaceutical, Sanofi, AbbVie, and PharmaEssentia Japan; and writing fees from PharmaEssentia Japan and PharmaEssentia Corporation. Haruna Kitamura, Koji Dohi, and Riki Yoshimoto are employees at LESPEDEZA, a division of EMC K.K., which was funded by the study sponsor.
